Pfizer Inc. (NYSE: PFE) continues to face pressure as COVID vaccine sales fade and revenue normalizes. The stock trades near $25/share, down sharply from past highs, reflecting weaker earnings and cautious sentiment. Still, analysts see a slow recovery supported by cost cuts, a solid balance sheet, and new drug launches in oncology and RSV.
Recently, Pfizer announced progress on several strategic fronts. The company’s BRAFTOVI + MEKTOVI combination showed encouraging long-term survival data in lung cancer, strengthening its oncology position. Pfizer also reached an agreement with U.S. regulators to improve pricing transparency and accelerate access to key drugs, signaling a stronger focus on sustainable growth. These developments show that Pfizer is working to rebuild confidence and transition from pandemic-driven sales to a more diversified, innovation-led model.
This article explores where Wall Street analysts think Pfizer could trade by 2027. We’ve pulled together consensus targets and valuation models to outline the stock’s potential path. These figures reflect current analyst expectations and are not TIKR’s own predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Modest Upside
Pfizer trades at about $25/share today. The average analyst price target is $29/share, which points to roughly 17% upside through 2027. Forecasts stay relatively tight, showing moderate confidence in a gradual recovery:
- High estimate: ~$36/share
- Low estimate: ~$24/share
- Median target: ~$29/share
- Ratings: 7 Buys, 1 Outperform, 15 Holds, 1 Sell
It looks like analysts see some room for gains, but expectations remain measured. For investors, this suggests the stock could edge higher as earnings stabilize and cost savings take effect. Pfizer’s steady cash flow and high dividend yield make it more attractive as an income compounder than a fast-growth play.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
Pfizer: Growth Outlook and Valuation
The company’s fundamentals remain soft but are showing signs of recovery:
- Revenue is projected to edge lower into 2027
- Operating margins are expected near 35%
- Shares trade around 9x forward earnings, below historical averages
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using an 8.6x forward P/E suggests ~$29/share by 2027
- That implies about 17% upside, or roughly 7% annualized returns
What it means for investors:
Even with a slight revenue decline, cost savings and mix shift can support margin repair. The undemanding multiple provides a cushion if growth stays slow, while the dividend does most of the heavy lifting. Pfizer screens as a steady value and income play with modest price appreciation potential.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
Pfizer’s cost discipline and restructuring progress are starting to show results. Management reaffirmed its multi-billion-dollar savings plan, aiming to simplify operations and rebuild margins. The integration of Seagen is also strengthening Pfizer’s oncology pipeline, adding high-value therapies that could offset the decline in COVID-related products.
New launches in vaccines and oncology remain key growth drivers. The company’s RSV vaccine rollout and oncology portfolio expansion have been well-received, supporting revenue visibility in the second half of the decade.
For investors, these improvements suggest Pfizer still has the tools to stabilize earnings and return to steady growth. While the turnaround is slow, the company’s diversified pipeline and strong balance sheet make it a reliable compounder for patient shareholders.
Bear Case: Limited Growth and Execution Risk
Even with these positives, Pfizer’s near-term growth story still faces challenges. Demand for COVID-related products continues to fade, and it may take time for new launches to pick up the slack. The company’s overall recovery is expected to be slow, with earnings progress coming in small steps rather than big leaps.
The main concern for investors is execution. If cost reductions or pipeline rollouts don’t go as planned, profitability could stay under pressure longer than the market expects.
Pfizer’s valuation offers some cushion, but without stronger momentum in its core portfolio, the stock could remain range-bound until investors see clearer signs of growth returning.
Outlook for 2027: What Could Pfizer Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model using an 8.6x forward P/E suggests Pfizer could trade near $29/share by 2027. That represents about 17% total upside, or roughly 7% annualized returns from current levels.
While this would mark a gradual recovery, it already assumes steady execution on cost savings and new drug launches. To deliver stronger upside, Pfizer would need faster-than-expected earnings growth from its oncology and vaccine pipelines.
For investors, Pfizer looks like a dependable long-term dividend play rather than a high-growth stock. Returns should come mostly from its yield and modest multiple expansion, making it a reasonable pick for those seeking steady income and lower volatility.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Click here to sign up for TIKR and get your free copy of TIKR’s 5 AI Compounders report today.
